TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06763159: A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20124 in Patients with Advanced Solid Tumors

Sponsor: Hansoh BioMedical R&D Company · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 450 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06763159 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06763159 Rescue Dossier →